Literature DB >> 15758251

Phytoestrogen alpha-zearalanol antagonizes oxidized LDL-induced inhibition of nitric oxide production and stimulation of endothelin-1 release in human umbilical vein endothelial cells.

Hai-Shan Xu1, Jinhong Duan, Shunling Dai, Yunqing Wu, Renyu Sun, Jun Ren.   

Abstract

Oxidative modification of low-density lipoprotein (LDL) leads to formation of the atherogenic molecule oxidized LDL (oxLDL), which is considered to be an important mediator for vascular endothelial dysfunction and atherosclerosis. It is speculated that reduced nitric oxide (NO) release/bioavailability and enhanced release of endothelin-1 (ET-1) may contribute to oxLDL-induced endothelial dysfunction. Estrogen may improve lipid profile and inhibit oxLDL-induced endothelial damage. However, estrogen replacement therapy has been suspended due to uncertainty in benefits versus risk (such as cancer progression) in postmenopausal women. This study was designed to evaluate the effect of a novel phytoestrogen, alpha-zearalanol (alpha-ZAL), on oxLDL-induced effect on NO and ET-1 production in human umbilical vein endothelial cells (HUVEC). HUVEC were incubated with oxLDL (50 microg/mL) for 24 h in the absence or presence of alpha-ZAL (0-1000 nM), 17beta-estradiol (E2, 10 nM), or the E2 receptor antagonist ICI182780 (1 microM). Levels of NO and ET-1 were measured by spectrophotometry and enzymatic immunoassay, respectively. NOS activity was evaluated by conversion of 3H-arginine to 3H-citrulline. Protein and mRNA expression of NOS and ET-1 were measured by Western blot and RT-PCR. Our results indicated that oxLDL significantly reduced NO release and NOS activity, and enhanced ET-1 pro-duction associated with reduced NOS3 (but not NOS2) expression and enhanced ET-1 mRNA expression. All these oxLDL-induced alterations were significantly attenuated or abolished by co-incubation with alpha-ZAL or E2, both through an E2 receptor-dependent mechanism. alpha-ZAL, E2, and ICI182780 had no effect on NO/ET-1 release, NOS activity, or expression of NOS and ET-1. These data suggested that the phytoestrogen alpha-ZAL, like E2, may effectively antagonize oxLDL-induced decrease in NO and increase in ET-1, which may be protective for endothelial function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15758251     DOI: 10.1385/ENDO:25:3:235

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  39 in total

1.  Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

Authors:  L Mosca; P Collins; D M Herrington; M E Mendelsohn; R C Pasternak; R M Robertson; K Schenck-Gustafsson; S C Smith ; K A Taubert; N K Wenger
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

Review 2.  Estrogen replacement therapy and cardioprotection: mechanisms and controversies.

Authors:  M T R Subbiah
Journal:  Braz J Med Biol Res       Date:  2002-03       Impact factor: 2.590

3.  Phytoestrogens reduce bone loss and bone resorption in oophorectomized rats.

Authors:  C R Draper; M J Edel; I M Dick; A G Randall; G B Martin; R L Prince
Journal:  J Nutr       Date:  1997-09       Impact factor: 4.798

Review 4.  The pivotal role of nitric oxide for vascular health.

Authors:  John P Cooke
Journal:  Can J Cardiol       Date:  2004-08       Impact factor: 5.223

Review 5.  Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.

Authors:  L J Lerner; V C Jordan
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

6.  17Beta-estradiol modulates endothelin-1 expression and release in human endothelial cells.

Authors:  A S Bilsel; H Moini; E Tetik; F Aksungar; B Kaynak; A Ozer
Journal:  Cardiovasc Res       Date:  2000-06       Impact factor: 10.787

7.  In vivo oestrogenicity and binding characteristics of alpha-zearalanol (P-1496) to different classes of oestrogen binding proteins in rat liver.

Authors:  C Mastri; P Mistry; G W Lucier
Journal:  J Steroid Biochem       Date:  1985-09       Impact factor: 4.292

8.  Phytoestrogenic isoflavones daidzein and genistein reduce glucose-toxicity-induced cardiac contractile dysfunction in ventricular myocytes.

Authors:  Kadon K Hintz; Jun Ren
Journal:  Endocr Res       Date:  2004-05       Impact factor: 1.720

Review 9.  Benefits and risks of estrogen replacement therapy.

Authors:  R A Lobo
Journal:  Am J Obstet Gynecol       Date:  1995-09       Impact factor: 8.661

10.  Oxidized LDL and lipoprotein(a) stimulate renin release of juxtaglomerular cells.

Authors:  J Galle; P Stunz; P Schollmeyer; C Wanner
Journal:  Kidney Int       Date:  1995-01       Impact factor: 10.612

View more
  3 in total

1.  Gypenoside XVII Prevents Atherosclerosis by Attenuating Endothelial Apoptosis and Oxidative Stress: Insight into the ERα-Mediated PI3K/Akt Pathway.

Authors:  Ke Yang; Haijing Zhang; Yun Luo; Jingyi Zhang; Min Wang; Ping Liao; Li Cao; Peng Guo; Guibo Sun; Xiaobo Sun
Journal:  Int J Mol Sci       Date:  2017-02-09       Impact factor: 5.923

2.  Gut Microbiota-Related Evidence Provides New Insights Into the Association Between Activating Transcription Factor 4 and Development of Salt-Induced Hypertension in Mice.

Authors:  Tian-Hao Liu; Wen-Cong Tao; Qiu-Er Liang; Wan-Qing Tu; Ya Xiao; Li-Guo Chen
Journal:  Front Cell Dev Biol       Date:  2020-11-13

3.  Treatment with phytoestrogen alpha-zearalanol might protect neurons of hippocampus in ovariectomized rats.

Authors:  Yi-Long Dong; Yun Yue; Feng-Hua Liu; Sen-Yang Lang; Xiao-Chun Zhang; Shun-Ling Dai; Qin-Sheng Ge; Ping-Ping Zuo
Journal:  Endocrine       Date:  2006-12       Impact factor: 3.925

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.